Aigen Investment Management LP Acquires New Position in IQVIA Holdings Inc. (NYSE:IQV)

Aigen Investment Management LP purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 7,873 shares of the medical research company's stock, valued at approximately $1,547,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter valued at $27,000. Synergy Asset Management LLC purchased a new stake in shares of IQVIA during the fourth quarter worth about $33,000. Avior Wealth Management LLC raised its stake in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. lifted its stake in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after purchasing an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in shares of IQVIA during the 3rd quarter worth $57,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Citigroup decreased their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday. Finally, StockNews.com raised IQVIA from a "hold" rating to a "buy" rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Price Performance

Shares of NYSE:IQV opened at $183.75 on Wednesday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $261.73. The firm has a market capitalization of $32.36 billion, a P/E ratio of 24.50, a P/E/G ratio of 1.99 and a beta of 1.48. The company's fifty day moving average price is $198.52 and its 200 day moving average price is $213.86.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.